Impact News +++ ANLEIHEN-Woche #KW34 – 2025: Energiekontor, JDC, The Platform Group, Aream, LEEF, Dt. Rohstoff,... (Anleihen-Finder) +++ PLATFORM GROUP Aktie +4,84%

Gewinn & Umsatz News zur TEVA Aktie

>TEVA Aktienkurs

15.65 EUR -3.4% (Tradegate)

Ask: 15.9 EUR / 350 Stück

Bid: 15.65 EUR / 400 Stück

Tagesumsatz: 10293 Stück

Realtime Kurs von 8 bis 22 Uhr!

TEVA Aktie über LYNX handeln

Intraday

1 Jahr

>TEVA Performance

1 Woche: +3,0%

1 Monat: +13,4%

3 Monate: +4,7%

6 Monate: -1,6%

1 Jahr: -5,2%

laufendes Jahr: -27,2%

>TEVA Aktie

Name:

TEVA PHARMACEUTICAL INDUSTRIES ADR

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8816242098 / 883035

Symbol/ Ticker:

TEV (Frankfurt) / TEVA (NYSE)

Kürzel:

FRA:TEV, ETR:TEV, TEV:GR, NYSE:TEVA

Index:

Webseite:

https://www.tevapharm.com..

Profil:

Teva Pharmaceutical Industries Ltd. ADR represents..
>Volltext..

Marktkapitalisierung:

17803.87 Mio. EUR

Unternehmenswert:

30993.54 Mio. EUR

Umsatz:

14328.88 Mio. EUR

EBITDA:

3899.28 Mio. EUR

Nettogewinn:

-130.55 Mio. EUR

Gewinn je Aktie:

-0.12 EUR

Schulden:

15038.23 Mio. EUR

Liquide Mittel:

1854.57 Mio. EUR

Operativer Cashflow:

1450.33 Mio. EUR

Bargeldquote:

0.18

Umsatzwachstum:

2.43%

Gewinnwachstum:

65.66%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

27.11.17 - 0.0783105€
25.08.17 - 0.0783105€

>weitere anzeigen...

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 891.185 USD.

Suchwörter:

TEVA

Letzte Datenerhebung:

23.08.25

>TEVA Kennzahlen

Aktien/ Unternehmen:

Aktien: 1146.84 Mio. St.

Frei handelbar: 99.9%

Leerverk. Aktien: 4.4%

Rückkaufquote: -

Mitarbeiter: 36167

Umsatz/Mitarb.: 0.39 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 39.59%

Bewertung:

KGV: -

KGV lG: 6.84

KUV: 1.26

KBV: 2.94

PEG-Ratio: -

EV/EBITDA: 7.95

Rentabilität:

Bruttomarge: 49.55%

Gewinnmarge: -0.91%

Operative Marge: 21.05%

Managementeffizenz:

Gesamtkaprendite: -0.37%

Eigenkaprendite: -2.31%

>TEVA Anleihen

Es sind 7 Anleihen zur TEVA Aktie bekannt.

>TEVA Peer Group

Es sind 601 Aktien bekannt.

>TEVA Chart & Kurs - NYSE

>TEVA Gewinn & Umsatz News

30.07.25 - 14:06	Teva again raises profit guidance (Globes)
	The Israeli pharmaceutical company beat the analysts on profit but missed on revenue in the second quarter of 2025....

22.05.25 - 23:18	Deckers Outlook Misses Expectations as Tariffs, Slowing Hoka Sales Apply Pressure (WSJ EN)
	The footwear company, which also owns Ugg and Teva, said it wouldn't share an outlook for fiscal-year 2026, citing macroeconomic uncertainties. Shares fell in after-hours trading....

07.05.25 - 14:01	ROUNDUP: Teva Pharma Boosts FY25 Adj. EPS Outlook (AFX)
	PETAH TIKVA (dpa-AFX) - While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) raised its adjusted earnings guidance for the full-year 2025......

07.05.25 - 13:39	Teva Pharm first-quarter profit rise tops estimates (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.01.25 - 13:54	Teva Pharma Guides FY25 Adj. EPS Below View; Q4 Results Top Estimates (AFX)
	PETAH TIKVA (dpa-AFX) - While reporting financial results for the fourth quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) initiated its adjusted earnings and revenue guidance for th......

18.12.24 - 16:36	Teva share price at 6-year high after trial results (Globes)
	The Israeli pharmaceutical company's market cap gained $5 billion in one Wall Street session boosting Israeli pension funds by hundreds of millions of dollars....

17.12.24 - 18:30	Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment (WSJ EN)
	Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies....

17.12.24 - 17:00	Teva jumps sharply on bowel disease drug results (Globes)
	Teva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn's disease....

17.12.24 - 14:04	Sanofi, Teva Say Duvakitug Positive Phase 2B Results Show Best-In-Class Potential (Reuters EN)
	BRIEF-Sanofi, Teva Say Duvakitug Positive Phase 2B Results Show Best-In-Class Potential Dec 17 (Reuters) - Sanofi SA SASY.PA : DUVAKITUG POSITIVE PHASE 2B RESULTS DEMONSTRATE BEST-IN-CLASS POTENTIAL IN ULCERATIVE COLITIS AND CROHN'S DISEASE 47.8% OF UC PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED CLINICAL REMISSION SANOFI AND TEVA TO INITIATE PHASE 3...

06.11.24 - 14:08	+++ Geschäftszahlen +++: Puma schafft Umsatzplus und sieht sich für Trump-Zölle gut gerüstet (Handelsblatt)
	BMW-Gewinn bricht ein +++ Ratiopharm-Mutter Teva verdient mehr +++ Unicredit hebt Gewinnprognose an +++ Die Geschäftszahlen des Tages....

02.11.24 - 04:48	Teva Presents New Research On Schizophrenia, Highlighting SOLARIS Trial Results For TEV-749 (AFX)
	PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social functioning and quality of life from the Phase ......

21.09.24 - 15:24	Teva Reports Positive Phase 3 Results For TEV-749 In Schizophrenia Treatment (AFX)
	PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and tolerability results for Phase 3 Subcutane......

31.07.24 - 15:40	Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary (Reuters EN)
	Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary...

31.07.24 - 13:54	Teva reports strong Q2 results, raises 2024 forecast (Globes)
	Teva CEO: We are also showing significant progress in on our late-stage innovative pipeline....

31.07.24 - 13:39	Teva Pharma raises annual profit view on strong sales of Huntington′s disease drug (Reuters EN)
	Teva Pharma raises annual profit view on strong sales of Huntington's disease drug...

31.07.24 - 13:26	Teva Pharma lifts annual profit view on strong generic, Huntington′s disease drug sales (Reuters EN)
	Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales...

29.07.24 - 15:28	Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 55 cents a share - Earnings Preview (Reuters EN)
	Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 55 cents a share - Earnings Preview...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Politiker verschweigt oft auch das, was er nicht weiß. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram